See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Bristol Myers Squibb Company (BMY) - free report >>
Johnson & Johnson (JNJ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Johnson & Johnson (JNJ) - free report >>
Image: Bigstock
Pfizer Investing $350M in China, Setting up Biotech Center
Pfizer Inc. (PFE - Free Report) is boosting its presence in China by setting up a state-of-the-art Global Biotechnology Center in the Hangzhou Economic Development Area (HEDA). The company will be investing about $350 million in the facility which will be Pfizer’s third biotechnology center globally and the first in Asia.
Pfizer intends to manufacture high-quality, affordable biosimilar medicines at the Center to cater to patients in China as well as across the world. The Center is scheduled to be completed in 2018. China remains an attractive investment area for several companies given the rising incidence of non-communicable diseases and an aging population.
We remind investors that Pfizer’s biosimilar portfolio was significantly enhanced with the acquisition of Hospira last year. Earlier this year, the company’s biosimilar version of Remicade gained FDA approval while key programs include biosimilar versions of Herceptin, Rituxan, Avastin, and Humira.
The biosimilars market represents huge commercial potential. On its first quarter call, Pfizer had mentioned that approximately $100 billion of currently patented branded biologics are expected to lose patent protection in the next 5 - 10 years. Moreover, the company said that the global market for biosimilars is expected to grow from around $1 billion annually in 2013 to $17 billion - $20 billion in 2020.
Pfizer is a Zacks Rank #1 (Strong Buy) stock. Other well-ranked large cap pharma stocks include Bristol-Myers Squibb Company (BMY - Free Report) , Johnson & Johnson (JNJ - Free Report) and Bayer AG (BAYRY - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>